Therapeutically, IL-2 blockade or modulation strategies, including low-dose IL-2 therapy aimed at selectively expanding regulatory T cells (Tregs) while suppressing pro-inflammatory B cell responses, could be explored as potential interventions in AKI. Here, IL2 is linked to acute kidney injury.